Premium
Bumetanide and furosemide
Author(s) -
Brater D Craig,
Chennavasin Polavat,
Day Bart,
Burdette Ann,
Anderson Shirley
Publication year - 1983
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1983.154
Subject(s) - bumetanide , furosemide , diuretic , bioavailability , chemistry , urine , pharmacology , excretion , endocrinology , oral administration , diuresis , medicine , sodium , renal function , cotransporter , organic chemistry
We assessed the response to and handling of furosemide and bumetanide in 30 experiments with the former and 46 with the latter in normal subjects. Oral doses of furosemide (20, 40, and 80 mg) were used, and subjects received oral doses of 0.5, 1, and 2 mg bumetanide and intravenous doses of 0.5 and 1 mg bumetanide. Both drugs were quickly absorbed and peak urinary amounts were reached at 75 min (median). Approximately 30% of an oral dose of each drug was excreted unchanged in the urine with no evidence of dose‐dependent elimination. After intravenous injection, 36% of the bumetanide was excreted unchanged. Consequently, bumetanide has an estimated bioavilability of 80% (approximately 40% for furosemide). The relationship between the logarithm of the urinary bumetanide excretion rate and the logarithm of the sodium excretion rate was described by a sigmoid‐shaped dose‐response curve, with a dose inducing half‐maximal response of 1 ± 0.04 μg/min; it was 69.8 μg/min for furosemide. Overall, the distinguishing features between the two drugs are the 200% greater bioavailability and the much greater potency of bumetanide. Clinical Pharmacology and Therapeutics (1983) 34 , 207–213; doi: 10.1038/clpt.1983.154